Clinical trial
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced…
NCT00040183 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00040183 |
|---|---|
| Title | OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. |
| Official title | A Randomized Placebo Controlled Study of OSI-774 (Tarceva (TM)) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Collaborators | Canadian Cancer Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Tarceva (erlotinib HCl, OSI-774) |
| Enrollment | 569 |
| Start date | Nov 29, 2001 |
| Primary completion | Jan 15, 2004 |
| Completion | Jan 15, 2004 |
| First posted | Jun 25, 2002 |
| Last update posted | Jan 10, 2018 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, Germany, Greece, Israel, Italy, Mexico, New Zealand and 5 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: